Details for Patent: 8,945,612

Which drugs does patent 8,945,612 protect, and when does it expire?

Patent 8,945,612 protects INBRIJA and is included in one NDA.

This patent has seventy-four patent family members in eighteen countries.

Summary for Patent: 8,945,612

Title:	Capsules containing high doses of levodopa for pulmonary use
Abstract:	The present invention provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L. The invention further provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L wherein the capsule material comprises hydroxypropylmethylcellulose (HPMC) and titanium dioxide.
Inventor(s):	Kee; Kevin D. (Somerville, MA), Penachio; Ernest D. (Haverhill, MA), Kamerkar; Abhijit (Boston, MA), Lipp; Michael M. (Framingham, MA), Batycky; Richard P. (Newton, MA)
Assignee:	Civitas Therapeutics, Inc. (Chelsea, MA)
Application Number:	14/174,179
Patent Claim Types: see list of patent claims	Compound; Device; Dosage form;

Drugs Protected by US Patent 8,945,612

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Acorda	INBRIJA	levodopa	POWDER;INHALATION	209184-001	Dec 21, 2018		RX	Yes	Yes			Y

International Family Members for US Patent 8,945,612

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013342246
Australia	2013342247
Australia	2013342248
Australia	2017279626